View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

Covenant Logistics Group Announces Quarterly Cash Dividend

Covenant Logistics Group Announces Quarterly Cash Dividend CHATTANOOGA, Tenn., May 17, 2024 (GLOBE NEWSWIRE) -- Covenant Logistics Group, Inc. (NASDAQ/GS: CVLG) (“Covenant” or the “Company”) announced today that its board of directors has declared a quarterly cash dividend of $0.11 per share of Class A and Class B common stock. The quarterly cash dividend is payable to stockholders of record on June 7, 2024, and is expected to be paid on June 28, 2024. The quarterly cash dividend is pursuant to a cash dividend program previously approved by the Company’s board of directors. The actual de...

 PRESS RELEASE

Optinose to Present at the H.C. Wainwright 2nd Annual BioConnect Inves...

Optinose to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ YARDLEY, Pa., May 17, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its management team will present a company overview and business update at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ on May 20, 2024 at 11:30 a.m. ET. To listen to a webcast of the presentation live, please visit the Investors page of the Optinose website. A replay...

Royal Caribbean Group: 1 director

A director at Royal Caribbean Group sold 24,201 shares at 140.210USD and the significance rating of the trade was 73/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years ...

 PRESS RELEASE

AMG Announces Partnership with Suma Capital

AMG Announces Partnership with Suma Capital WEST PALM BEACH, Fla., May 16, 2024 (GLOBE NEWSWIRE) -- AMG, a leading partner to independent investment management firms globally, today announced that it acquired a minority equity interest in Suma Capital (“Suma”). Suma is a pan-European private markets firm that invests in the transition to a lower carbon economy, a sector with increasing client allocations and deployment opportunities across Europe. Led by co-founders Enrique Tombas, David Arroyo, and Pablo Muller, Suma has approximately $800 million in assets under management primaril...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: May 15, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Century Aluminum Company Applauds Biden Administration Decision To Tri...

Century Aluminum Company Applauds Biden Administration Decision To Triple Chinese Aluminum Tariffs CHICAGO, May 14, 2024 (GLOBE NEWSWIRE) -- President Biden today announced that his administration would triple existing tariffs on Chinese aluminum imports pursuant to Section 301 of the Trade Act of 1974. Today’s action provides a clear and strong response to China’s unfair trade policies and will help to put a stop to China’s continuing build-up of overcapacity and non-market pricing actions. Jesse Gary, Century's (NASDAQ: CENX) President and Chief Executive Officer, who attended the Whit...

 PRESS RELEASE

Optinose Reports First Quarter 2024 Financial Results and Recent Opera...

Optinose Reports First Quarter 2024 Financial Results and Recent Operational Highlights Company reports Q1 2024 XHANCE net revenue of $14.9 million, an increase of 26% compared to Q1 2023 Company expects full year 2024 XHANCE net revenues to be between $85.0 to $95.0 million Company expects peak year XHANCE net revenues of at least $300 million from current specialist focused prescriber audience Company expects to produce positive income from operations (GAAP) for full year 2025 Conference call and webcast to be held today at 10:00 a.m. Eastern Time YARDLEY, Pa., May 14, 2...

Westlake Corp: 1 director

A director at Westlake Corp sold 3,500 shares at 158.500USD and the significance rating of the trade was 65/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly s...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: May 11, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Optinose Announces Reporting Date for First Quarter 2024 Financial Res...

Optinose Announces Reporting Date for First Quarter 2024 Financial Results Conference Call and Webcast to be held May 14, 2024, at 10:00 a.m. Eastern Time YARDLEY, Pa., May 10, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will report financial results for the first quarter 2024 and corporate updates, before market open, on Tuesday, May 14, 2024. Company to Host Conference CallMembers of the Company’s leadership team will host a conference call to discuss f...

Wedbush Research
  • Wedbush Research
TPX TEMPUR SEALY INTERNATIONAL INC
GEO GEO GROUP INC. (THE)
2454 MEDIATEK INC.
XNCR XENCOR INC.
XENE XENON PHARMACEUTICALS INC
WDC WESTERN DIGITAL CORPORATION
TSLA TESLA INC
TSCO TRACTOR SUPPLY COMPANY
TRIP TRIPADVISOR INC.
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
SBRA SABRA HEALTH CARE REIT INC.
QCOM QUALCOMM INC
PZZA PAPA JOHN'S INTERNATIONAL INC.
PSTG PURE STORAGE INC. CLASS A
OHI OMEGA HEALTHCARE INVESTORS INC.
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
NHI NATIONAL HEALTH INVESTORS INC.
MU MICRON TECHNOLOGY INC.
LTC LTC PROPERTIES INC.
LOW LOWE'S COMPANIES INC.
JCOM J2 GLOBAL INC.
INTC INTEL CORPORATION
HD HOME DEPOT INC.
GOOGL ALPHABET INC. CLASS A
35G GENPACT LIMITED
FB FACEBOOK INC. CLASS A
FATE FATE THERAPEUTICS INC
CXW CORECIVIC INC.
CRM SALESFORCE.COM INC.
CHUY CHUY'S HOLDINGS INC.
AXTI AXT INC.
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
FND FLOOR & DECOR HOLDINGS INC. CLASS A
ANAB ANAPTYSBIO INC.
OKTA OKTA INC. CLASS A
SNBR SLEEP NUMBER CORPORATION
MDB MONGODB INC. CLASS A
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
AVGO BROADCOM INC.
PRPL PURPLE INNOVATION
LEGH LEGACY HOUSING CORP
CRNC CERENCE
SMCI SUPER MICRO COMPUTER
U INC.
PLTR UNITY SOFTWARE
VOR PALANTIR TECHNOLOGIES
PLTK VOR BIOPHARMA
SNOW PLAYTIKA HOLDING
RBLX SNOWFLAKE INC. CLASS A
GHLD ROBLOX
MRVL GUILD HOLDINGS
STX MARVELL TECHNOLOGY INC
ALIT SEAGATE TECHNOLOGY HLDGS PLC
UWMC FOLEY TRASIMENE ACQUISITION CORP
ATXS UWM HLDGS CORP
CCSI ASTRIA THERAPEUTICS INC
GFS CONSENSUS CLOUD SOLUTIONS INC
TYRA GLOBALFOUNDRIES INC
SOUN TYRA BIOSCIENCES INC
GETY SOUNDHOUND AI INC
GTBIF GETTY IMAGES HOLDINGS INC
SKLZ GREEN THUMB INDUSTRIES INC.
DNTH SKILLZ INC
DIANTHUS THERAPEUTICS INC
Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: May 9, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Anaptys Announces First Quarter 2024 Financial Results and Provides Bu...

Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update Enrollment ongoing for global Phase 2b trial to treat atopic dermatitis (AD) with ANB032, our BTLA agonist; reiterating top-line data anticipated by year-end 2024Enrollment ongoing for global Phase 2b trial to treat rheumatoid arthritis (RA) and global Phase 2 trial to treat ulcerative colitis (UC) with rosnilimab, our PD-1 agonist; reiterating top-line data anticipated by mid 2025 and H1 2026, respectivelyIND submissions for ANB033 (anti-CD122 antagonist) and ANB101 (BDCA2 modulator) anticipated Q2 2024 and...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch